Answers are grounded in this paper and cite their sources.
Cooccurrence of multiple actionable protein/pathways alterations in each subtype indicates unique therapeutic vulnerabilities and opportunities for optimal combination therapy for this understudied and heterogeneous disease.
No takes yet. Share an insight, caveat, or question.
Ferrarotto et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: